Fulcrum Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 24.76 million compared to USD 26.14 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.49 USD | -7.29% | -15.82% | -3.85% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.85% | 403M | |
+34.01% | 51.07B | |
+33.84% | 38.86B | |
-8.02% | 38.78B | |
-8.98% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023